Login to Your Account

Lucentis' Phase III Data Show DME Improvements

By Tom Wall

Friday, March 11, 2011
Genentech reported that data from the first of two pivotal Phase III studies of Lucentis (ranibizumab injection) in diabetic macular edema (DME) showed "rapid and sustained improvement in vision" compared to a placebo injection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription